Hiring in life sciences? Share your open positions with our professional community. Read more Close

Advertisement

Tetracycline-loaded nanomotors target neutrophil activation and oxidative stress in acute lung injury.

Created on 15 Aug 2026

Authors

Saiqi Li, Ziqiang Zhang, Qianyun Zhang, Yi Shen, Chong Zhang, Jia Huang, Fan Su, Yuning Sun

Published in

iScience. Volume 29. Issue 8. Pages 117106. Aug 21, 2026. Epub Aug 06, 2026.

Abstract

Acute lung injury (ALI) has high mortality, underscoring the urgent need for effective therapies. Excessive inflammation, mainly driven by neutrophil activation and caspase-1-mediated IL-1β/IL-18 release, along with oxidative stress, plays a pivotal role in ALI progression. Tetracycline (TH) has shown promise in suppressing caspase-1-inflammasome signaling, and its therapeutic efficacy could be further enhanced through targeted delivery. Here, we developed a nitric oxide (NO)-driven nanomotor for reactive oxygen species (ROS)-responsive TH delivery (PMA@TH), enabling precise TH delivery to inflammatory lung tissues. Upon intratracheal administration, PMA@TH migrates to injury sites with high ROS concentrations to achieve precise drug release and the generated NO further enhances tissue penetration. The nanomotor not only inhibits neutrophil infiltration but also promotes macrophage M2 polarization, mitigating both local and systemic inflammation. Transcriptomic analysis further confirmed the dual anti-inflammatory and antioxidant effects of PMA@TH. This strategy demonstrates superior therapeutic outcomes in ALI models, offering a promising nanomedicine for clinical translation.

PMID:
42602995
Bibliographic data and abstract were imported from PubMed on 15 Aug 2026.

Read full publication at:
Please sign in to see all details.

Advertisement

Stats

  • Community rating n/a 0 votes
  • Reviewers' rating n/a 0 votes
  • Your rating

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

  • Recommendations n/a n/a positive of 0 vote(s)
  • Views 3
  • Comments 0

Recommended by

  • No recommendations yet.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.

Advertisement